BFBIO FY26 profit surges 41%

According to Mettis Global, BF Biosciences Limited (PSX: BFBIO) reported a 41 per cent rise in net profit for the year ended June 30, 2026, reaching Rs632.13m against Rs447.15m a year earlier. Earnings per share climbed to Rs7.16 from Rs5.52 in FY25. The report attributed the gain mainly to higher sales volumes and a 79 per cent gain in gross profit.

Net revenue grew 62 per cent to Rs9.46bn from Rs5.84bn, while cost of goods sold rose 51 per cent to Rs5.37bn. That left gross profit at Rs4.09bn, against Rs2.29bn a year earlier. Selling and distribution expenses jumped 87 per cent to Rs2.7bn, and operating profit grew 38 per cent to Rs1.17bn despite a 15 per cent fall in other income.

Finance costs fell 17 per cent to Rs105.96m, easing the company's debt burden. Profit before taxation rose 47 per cent to Rs1.06bn after minimum tax differentials of Rs10.64m were deducted. The income tax charge rose 55 per cent to Rs424.64m for the year.